Incidence and Recurrence of Melanoma Are Equivalent

Share this content:

the Cancer Therapy Advisor take:

Findings presented at the American Academy of Dermatology summer meeting showed a similar rate of diagnosis of in situ or invasive melanoma compared with the long-term risk of invasive melanoma recurrence.

 

A diagnosis of invasive melanoma compared with a diagnosis of in situ melanoma had an increased risk of invasive recurrence within 2 years of diagnosis. After that 2 year window, the risk of invasive recurrence was equivalent to the risk of diagnosis of either disease.

 

As a result, the follow-up for patients with in situ melanoma or invasive melanoma should be identical. The 40-year retrospective study used data from the Surveillance, Epidemiology, and End Results (SEER) program for 1973 to 2011.

 

Investigators identified 55,661 patients with a diagnosis of in situ melanoma, 97,614 patients with locally invasive melanoma, and 14,999 patients with regional or distant invasive melanoma. Those with a diagnosis of in situ melanoma had a hazard of invasive recurrence of 1.0, while the localized group and the regional/distant group had a hazard ratio of 1.03 and 1.08, respectively.

Research Targets Genetics of Melanoma
Diagnosis of in situ or invasive conferred a similar long-term risk of invasive melanoma recurrence.
A diagnosis of in situ or invasive melanoma conferred a similar long-term risk of invasive melanoma recurrence, a 40-year retrospective review showed.

For the first 2 years after initial diagnosis, invasive melanoma had a greater risk of invasive recurrence, as compared with an initial diagnosis of in situ disease.

Thereafter, the risk of invasive recurrence remains the same, regardless of the initial diagnosis, Hyemin Pomerantz, MD, of Brown University in Providence, R.I., reported here at the American Academy of Dermatology summer meeting.

READ FULL ARTICLE From Medical Page Today

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs